Physician profile
Andrea Ellis
NPI 1770070898
$1,880.45
in general payments reported to CMS, 2019-2025
14 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $577 · 2022: $705 · 2023: $186 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.75 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $293.05 | 2021-2025 | Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $283.68 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.57 | 2021-2023 | |
| Alkermes, INC. | $155.57 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $130.60 | 2021-2023 | Invega Sustenna |
| Luye Pharma (USA) Ltd. | $64.56 | 2025 | Erzofri Extended-Release |
| Axsome Therapeutics, INC. | $48.04 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $46.49 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $33.65 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $33.42 | 2021-2023 | Ingrezza |
| Vanda Pharmaceuticals INC. | $33.36 | 2021-2023 | Hetlioz, Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30.63 | 2025 | Rejoyn |
| Indivior INC. | $29.08 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.